RT Journal Article
SR Electronic
T1 Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.05.20031500
DO 10.1101/2020.03.05.20031500
A1 Cappuccini, Federica
A1 Bryant, Richard
A1 Pollock, Emily
A1 Carter, Lucy
A1 Verrill, Clare
A1 Hollidge, Julianne
A1 Poulton, Ian
A1 Baker, Megan
A1 Mitton, Celia
A1 Baines, Andrea
A1 Meier, Armin
A1 Schmidt, Guenter
A1 Harrop, Richard
A1 Protheroe, Andrew
A1 MacPherson, Ruth
A1 Kennish, Steven
A1 Morgan, Susan
A1 Vigano, Selena
A1 Romero, Pedro
A1 Evans, Thomas
A1 Catto, James W.F.
A1 Hamdy, Freddie
A1 Hill, Adrian V.S.
A1 Redchenko, Irina
YR 2020
UL http://medrxiv.org/content/early/2020/03/09/2020.03.05.20031500.abstract
AB Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for a decade. However, neither of the two clinically most developed prostate cancer vaccines, Sipuleucel-T and ProstVac, induce strong T cell immunity. In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa. Forty patients, either newly diagnosed with early stage prostate cancer and scheduled for radical prostatectomy or patients with stable disease on an active surveillance protocol, were recruited to the study to assess the vaccine safety and T cell immunogenicity. Secondary and exploratory endpoints included immune infiltration into the prostate, prostate specific antigen (PSA) change and assessment of phenotype and functionality of antigen-specific T cells. The vaccine had an excellent safety profile. Vaccination-induced 5T4-specific T cell responses were measured in blood by ex vivo IFN-γ ELISpot and were detected in the majority of patients with a mean level in responders of 198 spot-forming cells (SFC) per million peripheral blood mononuclear cells (PBMCs). Flow cytometry analysis demonstrated the presence of both CD8+ and CD4+ polyfunctional 5T4-specific T cells in the circulation. 5T4-reactive tumour infiltrating lymphocytes (TILs) were isolated from post-treatment prostate tissue. Some of the patients had a transient PSA rise 2-8 weeks following vaccination, possibly indicating an inflammatory response in the target organ. The potent T cell responses elicited support the evaluation of these vectored vaccine in efficacy trials.Competing Interest StatementAdrian VS Hill is a co-founder of and shareholder in Vaccitech Ltd which has supported the Oxford prostate cancer vaccine programme. The other authors declare that they have no competing interests.Clinical TrialNCT02390063Funding StatementThis research was supported by the European Union’s Seventh Framework Programme under grant agreement No. 602705.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, IR, upon reasonable request.